Bochie that jump in sales is mainly a function of screening sales taking off.
Realisticaly it will take GBI a few years to build up a reasonable set of data (marketing material) for screening sales to become meaningful...that number in 2012 assumes a PapType market share of 10% of screening tests and 50% of Australia & NZ markets.
In screening market 2010 market share assumed is 2% whilst 2011 is 4%.
The ASCUS/triage sales from 2010-2011 are the low hanging fruit so to speak and can get GBI profitable whilst building the data for the larger screening market.
cheers
- Forums
- ASX - By Stock
- GBI
- gbi valuation - part 2
gbi valuation - part 2, page-3
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
MND
Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?